Share

    


Home / Search Results

Search Results

Search Publications

Search Again?

Filter By Content Type

Filter By Topic

Our Supporter
Electronic Health Records (EHR) Integrations for Biomarker Testing: Roadmap The EHR Integrations for Biomarker Testing Roadmap is an interactive learning tool that can help multidisciplinary cancer care teams acquire insights on initiating, preparing for, implementing, and evaluating EHR biomarker testing integrations. This roadmap equips multidisciplinary cancer care teams with essential information …
ACCC would like to recognize the members of the EHR Integration advisory committee.
The 4Ms Framework of Age-Friendly Care The 4Ms — What Matters, Medication, Mentation, and Mobility — make care of older adults that can be complex, more manageable. The 4Ms identify the core issues that should drive all care and decision making with the care of older adults. They organize care and focus on the older adult’s wellness and strengths rather than solely on disease. The 4Ms are relevant …
Findings from this program will help guide development of future initiatives and resources cancer programs can utilize to address current barriers to biomarker testing and to optimize care delivery for Medicaid beneficiaries.
During the past few years, scientific journals have published an increasing number of groundbreaking articles about the efficacy of employing T-cell bispecific antibodies (TRBAs) in cancer immunotherapy. The research is encouraging: More than 50 bispecific antibodies are currently in clinical trials. Below are links to recent scholarship and resources that can help practices better serve their patients …
The project explored the reasons for, and develop suggestions to correct, discrepancies in the treatment journey for patients with multiple myeloma who receive ASCT as part of their therapy.
ACCC is conducting this education program to understand how the current dispensing landscape is affecting delivery of oral therapies for patients with multiple myeloma.
ACCC has developed an educational initiative to raise awareness among cancer programs about treatment options for newly diagnosed patients with multiple myeloma who are ineligible for transplant.
The goal of this work is to identify the knowledge and practice gaps among community oncology practitioners relative to the evolving treatment landscape of Multiple Myeloma.
The aim of this project is to reframe the conversation between patients and providers to incorporate new therapy advancements, set expectations with patients about their treatment journey, and give them more confidence that there is new hope.
ACCC would like to acknowledge our committee members for the Advancing Care for Patients with Myeloproliferative Neoplasms project.
Hereditary prostate cancers account for about 5%-10% of all prostate cancers and approximately 1 in 8 men will receive a prostate cancer diagnosis in their lifetime.1 Advancements in the genetics of prostate cancer have shown that the presence of key germline mutations is associated with a higher risk of developing prostate cancer and the cancers associated with these mutations tend to be more …
To optimize care for patients being treated with bispecific antibodies and to explore early identification and management of adverse events common in patients on bispecific antibodies, ACCC has developed an educational initiative.
In response to the need for cancer screening and care in Appalachia, ACCC—together with several of its state chapters—launched the Appalachian Community Cancer Alliance in December 2021.
Ovarian cancer ranks fifth in cancer deaths among U.S. women. According to American Cancer Society estimates, in 2021, more than 21,000 people were diagnosed with ovarian cancer, and nearly 14,000 people died from the disease.
This program explores current barriers in care coordination and therapy options for patients who are not eligible for transplant, as well as highlights strategies and best practice guidelines to improve outcomes for patients with acute myeloid leukemia.
By highlighting best practices and sharing written guidelines, ACCC hopes that when BsAbs therapy for solid tumors becomes available, care providers will feel confident administering the treatment in community and rural cancer programs.
Advancements in the delivery of chimeric antigen receptor (CAR) T-cell therapy have led to a growing urgency to expand access across a range of care delivery settings.
The ACCC Eliminating Precision Medicine Disparities project is focused on understanding specific barriers and challenges to equal access to precision medicine among underserved patient communities.